Standard BioTools Soars 17.14% on SomaLogic Sale to Illumina

On June 23, 2025, Standard BioTools saw a significant pre-market rise of 17.14%, marking a notable surge in investor interest and market sentiment.

Standard BioTools has announced a strategic sale of SomaLogic to Illumina, Inc. for an aggregate cash consideration of up to $425 million. This transaction includes an upfront payment of $350 million in cash and up to $75 million in near-term milestone payments. The deal also involves specified sales royalties on SOMAmer-based next-generation sequencing (NGS) library preparation kits, known as Illumina Protein Prep. Standard BioTools will retain certain Single SOMAmer reagent commercialization rights, ensuring continued participation in the long-term success of the technology.

The sale is expected to simplify Standard BioTools' operating structure, enabling the company to achieve adjusted EBITDA break-even. The transaction is part of a broader strategy to pursue disciplined M&A activities, focusing on acquiring high-potential assets with validated science and a clear path to commercialization. This approach aims to drive long-term value creation and profitability, aligning with the economic interests of shareholders.

Michael Egholm, President and CEO of Standard BioTools, highlighted the company's transformation since acquiring SomaLogic 18 months ago. The strategic sale to Illumina is seen as a pivotal move to integrate capabilities under one roof and lead SomaScan into its next phase of growth. The transaction reflects the fundamental improvements made to the business and positions Standard BioTools for future inorganic growth and value creation.